Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03189823
Other study ID # HenssenD
Secondary ID
Status Completed
Phase N/A
First received June 7, 2017
Last updated June 15, 2017
Start date January 1, 2003
Est. completion date December 31, 2016

Study information

Verified date June 2017
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In order to create insights in the effects of Motor cortex stimulation (MCS) on intractable pain, an open observational study was started in 2003. The aim of this research is to:

1. to determine the clinical effectivity of MCS on pain intensity after 1 month, 1 year and 3 years of stimulation

2. to determine the clinical effectivity of MCS on QoL and daity medication intake after 3 years of MCS


Description:

2.1 Study protocol In 2003, an observational study protocol was set up in the university medical centers of Nijmegen and Groningen, the Netherlands, in order to study the effects of MCS in patients that suffered from chronic neuropathic pain. Patients were included between 2005 and 2013 when they suffered from chronic intractable pain and reported high levels of pain (VAS > 5, measured three times daily during four days) and when the chronic neuropathic pain had showed to be intractable. Furthermore, on radiographic imaging techniques performed less than three years before inclusion for the implantation of MCS should show a possible conflict that might contribute to the pain. A multidisciplinary approach by the anesthesiologist-pain specialists, neurosurgeons, and clinical psychologists was chosen for the selection of patients. Patients with severe, current psychological problems (e.g., depression, high anxiety) or substance-abuse were excluded. Other exclusion criteria were the use of therapeutic anticoagulants, cognitive and/or psychiatric disorders in the medical history, nociceptive pain, an expected life expectancy less than 3 years due to other diseases (e.g., cancer), contra- indications for general anesthesia (e.g., severe cardio-pulmonal diseases), convulsive disorders and the presence of other neuromodulation systems. All patients underwent preoperative somatosensory-evoked potential (SSEP) measurement to determine the integrity of the somatosensory system in order to facilitate intra-operative neurophysiological monitoring. A MRI-scan was used to determine any anatomical contra-indications (brain atrophy, pathological structures) for the operative procedure. All patients presented in this study had a follow up of three years.

2.2 Surgical technique The pre-operative fMRI was fused with the neuronavigation MRI. For this purpose, cortex surface rendering technique was performed using the Stealthviz software (Medtronic Inc., Minneapolis, MN, USA) to visualize the cortical areas and determine the central sulcus and the motor cortex, which then was marked on the skin by using neuronavigation. All patients were operated under general anesthesia without muscle relaxation. A small craniotomy (approximately 4 × 4 cm) was carried out over the central sulcus. An electrode was placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA). A phase-reversal somatosensory-evoked potential was used to confirm the position of the central sulcus, thereafter cortical stimulation was performed to map functional motor areas. Following identification of the optimal target, the electrode was sutured to the dura mater. After placement of the electrode, the electrode was tunneled subcutaneously and connected with an internalized pulse generator (IPG) (Medtronic Versitrel and later Prime Advanced) that was implanted in the subclavian space or in a subcutaneous abdominal pocket.

2.3 Data-analysis An independent researcher, who was blinded to the stimulation conditions, investigated the patient records in this observational study. Only patients who were treated in accordance to the aforementioned treatment protocol and with a minimal follow-up of three years in whom the effect of MCS, occurrence of complications, daily intake of medication and change in quality of life was complete, were analyzed.

2.4 Ethical statement and registration of clinical trial This observational study was performed under the approval of the medical ethical committee of the region Arnhem-Nijmegen. All patients, after extensive pre-operative information, gave written informed consent due to the experimental nature of this treatment at that time. This clinical trial was not registered in 2003 due to the fact that, in The Netherlands, MCS was not an experimental method at that moment. The authors confirm that all ongoing and related trials for this intervention are registered

2.5 Assessment Pain is a complex, subjective and multidimensional phenomenon that is difficult to measure by unidimensional pain scores only. Apart from the visual analog scale (VAS), the intake of pain medication is thought to be a valid tool of measuring pain relief. Adding analgesic drug intake as an outcome parameter could provide a more realistic assessment of long-term benefits of MCS. Four outcome variables were examined: 1) the amount of pain relief, measured by the mean difference between VAS score pre-operatively and the VAS score during the follow-up (1 month, 6 months, 1 year, and 3 years after implantation of the MCS electrodes); 2) the change in the drug regimen of all patients per day; 3) adverse events (infection, bleeding, hardware removal, temporary seizures, and battery dysfunction); and 4) the correlation between stimulation parameters and the pain relief per patient. Pain relief was divided into three categories. A good pain relief, level 1, was defined as a VAS reduction of 70-100%. Reduction of pain according to a VAS scores change between 40% and 69% was defined as satisfactory (level 2), while a minimal pain relief was defined as a reduction of ≤ 40% on the VAS scores. An effective pain relief was defined as ≥ 40% reduction of pain (levels 1 and 2). The use of medication was monitored using the electronic patient record during follow-up. The medication quantification scale (MQS) was used in order to quantify medication use and was calculated for each drug by multiplying the dosage levels by their respective detriment weight. The dosage levels (0-6) were based on the recommended daily dosage range as described by Masters Steedman et al. These scores are summed to provide a quantitative index of total drug intake suitable for statistical analysis. The occurrence of complications was documented as well. Apart from biological complications (eg. bleeding, infection), the removal of the hardware due to a minimal effect was evaluated as well. To determine whether there was a correlation between the used stimulation parameters and the pain relief, the used stimulation parameters (intensities [V], pulse widths [µs], and frequencies [Hz]) were reviewed. Interference of pain with quality of life (QoL) was measured before and after (> 1 year) MCS with use of the Quality of Life Index (QLI), based on the Dutch version of the McGill pain questionnaire (MPQ-DLV).

2.6 Statistical analysis IBM SPSS Statistics version 22 was used for statistical analyses of the retrieved data (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). To analyze the differences in pain relief and MQS scores and QoL-indices per subgroup, the Mann-Whitney U test was used. In order to correlate the applied stimulation parameters, the Spearman rank correlation coefficient was conducted. Values are represented as mean ± standard deviation (minimum- maximum). Alterations in MQS scores and QoL-indices before and after MCS were calculated with use of the Wilcoxon signed-rank test. Statistical tests were two sided and with a significance level of P < 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date December 31, 2016
Est. primary completion date December 31, 2016
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

Patients were included between 2005 and 2013 when they suffered from chronic intractable pain and reported high levels of pain (VAS > 5, measured three times daily during four days) and when the chronic neuropathic pain had showed to be intractable. Furthermore, on radiographic imaging techniques performed less than three years before inclusion for the implantation of MCS should show a possible conflict that might contribute to the pain. A multidisciplinary approach by the anesthesiologist-pain specialists, neurosurgeons, and clinical psychologists was chosen for the selection of patients.

Exclusion Criteria:

Patients with severe, current psychological problems (e.g., depression, high anxiety) or substance-abuse were excluded. Other exclusion criteria were the use of therapeutic anticoagulants, cognitive and/or psychiatric disorders in the medical history, nociceptive pain, an expected life expectancy less than 3 years due to other diseases (e.g., cancer), contra- indications for general anesthesia (e.g., severe cardio-pulmonal diseases), convulsive disorders and the presence of other neuromodulation systems.

Study Design


Intervention

Device:
Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA
In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Outcome

Type Measure Description Time frame Safety issue
Other Occurence of complications The occurrence of complications was documented as well. Apart from biological complications (eg. bleeding, infection), the removal of the hardware due to a minimal effect was evaluated as well using the (electronic) patient record during 3 years postoperative
Primary Changes in pain intensity According to VAS scores 1month, 6months, 1 year and 3 years postoperative
Secondary Changes in quality of life Interference of pain with quality of life (QoL) was measured before and after (> 1 year) MCS with use of the Quality of Life Index (QLI), based on the Dutch version of the McGill pain questionnaire (MPQ-DLV) 3 years postoperative
Secondary Changes in daily medication intake The use of medication was monitored using the (electronic) patient record before MCS and during follow-up. The medication quantification scale (MQS) was used in order to quantify medication use and was calculated for each drug by multiplying the dosage levels by their respective detriment weight(21). The dosage levels (0-6) were based on the recommended daily dosage range as described by Masters Steedman et al.(22). These scores are summed to provide a quantitative index of total drug intake suitable for statistical analysis. 3 years postoperative
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03887494 - Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY) N/A
Recruiting NCT05761392 - APP-based Precise Management System of Chronic Intractable Pain N/A
Suspended NCT05067257 - Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer Phase 2
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Withdrawn NCT01951911 - Effectiveness of Ketamine in Malignant Neuropathic Pain Relief Phase 3
Completed NCT04701008 - Efficacy of Ketamine in Post Anesthesia Recovery Room
Completed NCT03350256 - BurstDR™ micrOdosing stimuLation in De-novo Patients N/A
Completed NCT04602286 - How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample) N/A
Completed NCT04625504 - Investigating Biological Targets, Markers, and Intervention for Chronic Pain N/A
Recruiting NCT05398003 - Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M) N/A
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Completed NCT00216684 - Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics Phase 3
Recruiting NCT05775510 - Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
Active, not recruiting NCT04727216 - Intermittent vs. Continuous Dorsal Root Ganglion Stimulation N/A
Completed NCT02091076 - Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing Phase 1/Phase 2
Completed NCT01166906 - Pain Blocking During Drug Administration or Blood Collection With Needles
Recruiting NCT04876469 - Radiocontrast Media in the Pulsed Radiofrequency Treatment N/A
Completed NCT05108103 - Determination of Longus Colli Muscle Thickness by Ultrasonography
Completed NCT04727749 - Pawsitive Impacts of Therapy Dog Visits N/A
Completed NCT04096391 - Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population N/A

External Links